Table 2.

Comparison of anti-MDA5 and anti-Ro52 antibody levels between patients with MDA5+DM in the survival and non-survival groups

	Non-survival group (N = 32)	Survival group (N = 94)	P-value
MDA5, no. (%)
Weak (1+)	2 (6.3)	11 (11.7)	0.590
Moderate (2+)	3 (9.4)	12 (12.8)	0.845
Strong (3+)	27 (84.4)	71 (75.5)	0.299
Ro52, no. (%)
Negative	6 (18.8)	44 (46.8)	0.005
Weak (1+)	1 (3.1)	11 (11.7)	0.281
Moderate (2+)	4 (12.5)	11 (11.7)	1.000
Strong (3+)	21 (65.6)	28 (29.8)	< 0.001

Data presented as number and percentage. Bold text highlights the significance

MDA5+DM, anti-MDA5 dermatomyositis